Department of Surgery, Divisions of Surgical Sciences and Neurosurgery, Duke University School of Medicine, 103 Research Drive, Durham, NC 27710, USA.
Cancer Lett. 2010 Aug 1;294(1):101-10. doi: 10.1016/j.canlet.2010.01.028. Epub 2010 Feb 13.
EGFR and its constitutively activated variant EGFRvIII are linked to glioblastoma resistance to therapy, the mechanisms underlying this association, however, are still unclear. We report that in glioblastoma, EGFR/EGFRvIII paradoxically co-expresses with p53-upregulated modulator of apoptosis (PUMA), a proapoptotic member of the Bcl-2 family of proteins primarily located on the mitochondria. EGFR/EGFRvIII binds to PUMA constitutively and under apoptotic stress, and subsequently sequesters PUMA in the cytoplasm. The EGFR-PUMA interaction is independent of EGFR activation and is sustained under EGFR inhibition. A Bcl-2/Bcl-xL inhibitor that mimics PUMA activity sensitizes EGFR/EGFRvIII-expressing glioblastoma cells to Iressa. Collectively, we uncovered a novel kinase-independent function of EGFR/EGFRvIII that leads to tumor drug resistance.
表皮生长因子受体(EGFR)及其组成性激活变体 EGFRvIII 与胶质母细胞瘤对治疗的耐药性有关,但这一关联的机制尚不清楚。我们报告称,在胶质母细胞瘤中,EGFR/EGFRvIII 与 p53 上调的凋亡调节剂(PUMA)反常共表达,后者是 Bcl-2 蛋白家族的一种促凋亡成员,主要位于线粒体上。EGFR/EGFRvIII 与 PUMA 持续结合,在凋亡应激下,随后将 PUMA 隔离在细胞质中。EGFR-PUMA 相互作用不依赖于 EGFR 的激活,并在 EGFR 抑制下持续存在。一种模拟 PUMA 活性的 Bcl-2/Bcl-xL 抑制剂可使表达 EGFR/EGFRvIII 的胶质母细胞瘤细胞对易瑞沙敏感。总的来说,我们揭示了 EGFR/EGFRvIII 的一种新的非激酶依赖的功能,导致肿瘤耐药。
Int J Mol Sci. 2024-6-6
Sci Signal. 2013-3-26
Cell Chem Biol. 2025-2-20
Biomolecules. 2023-6-16
Int J Mol Sci. 2021-1-13
Front Oncol. 2019-8-23
Oncogene. 2018-1-11
Curr Mol Pharmacol. 2010-1
Nat Rev Cancer. 2009-7
Neuro Oncol. 2009-4